Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prazosin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: CROSSOVER COMPARATIVE PHARMACOKINETIC STUDY OF TWO 3MG PRAZOSIN SUSTAINED RELEASE DELIVERY SYSTEMS: SIXTEEN HOUR VS TWENTY HOUR 85% RELEASE TIMES
    Active substance: PRAZOCIN
    Study summary document link (including results):
    View full study record
    Document reference: 46105
    Study title: TO CONFIRM THE EFFICACY AND TOLERANCE OF TREATMENT WITH PRAZOSIN ASSOCIATED WITH CHLORTHALIDONE AND WITH FUROSEMIDE IN PATIENTS WITH ESSENTIAL HYPERTENSION.
    Active substance: PRAZOCIN
    Study summary document link (including results):
    View full study record
    Document reference: 46110
    Study title: TO DETERMINE WHETHER THE ADDITION OF ORALLY ADMINISTERED PRAZOSIN IMPROVES PULMONARY FUNCTION IN PATIENTS WITH CHRONIC ASTHMA.
    Active substance: PRAZOCIN
    Study summary document link (including results):
    View full study record
    Document reference: 46111
    Study title: LONG TERM FOLLOW-UP EXPERIENCE IN A MINIZIDE TABLET (0.5MG PRAZOSIN/0.25MG POLYTHIAZIDE) MULTICENTER TRIAL
    Active substance: PRAZOCIN /POLYTHIAZIDE
    Study summary document link (including results): MZ-76-03 EMA Pediatrics Web Synopsis.pdf
    View full study record
    Document reference: 46107
    Study title: Minizide (Brand of Prazosin/Polythiazide) Tablets (0.5 mg/0.25 mg) Clinical Experience in a Non-Comparative, Multicenter Trial
    Active substance: PRAZOCIN /POLYTHIAZIDE
    Study summary document link (including results): MZ-76-01 and MZ-76-02 EMA Pediatric Web Synopsis.pdf
    View full study record
    Document reference: 46108
    Study title: Minizide (Brand of Prazosin/Polythiazide) Tablets (0.5 mg/0.25 mg) Clinical Experience in a Non-Comparative, Multicenter Trial
    Active substance: PRAZOCIN /POLYTHIAZIDE
    Study summary document link (including results): MZ-76-01 and MZ-76-02 EMA Pediatric Web Synopsis.pdf
    View full study record
    Document reference: 46109
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 14:19:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA